Download PDF
Arthritis und Rheuma 2009; 29(02): 81-93
DOI: 10.1055/s-0037-1620152
Kinder- und Jugendrheumatologie
Schattauer GmbH

Die medikamentöse Therapie der juvenilen idiopathischen Arthritis bei Kindern

Treatment of juvenile idiopathic arthritis
G. Horneff
1   Asklepios Klinik Sankt Augustin
› Author Affiliations
Further Information

Publication History

Publication Date:
22 December 2017 (online)

    Permissions and Reprints

Zusammenfassung

Die Therapie der juvenilen idiopathischen Arthritis erfolgt durch eine Kombination von nichtsteroidalen Antirheumatika, systemischen und/oder intraartikulären Glukokortikoiden, klassischen Basistherapeutika, Immunsupressiva und Biologika. Die neuen bio-logischen Medikamente erwiesen sich als au-ßerordentlich wirksam, auch bei schweren oder bislang therapierefraktären Verläufen. Drei Tumor-Nekrose-Faktor-Inhibitoren (Eta-nercept, Adalimumab und Infliximab) wurden bereits untersucht. Weitere therapeutische Optionen bestehen durch Inhibition von Interleukin-1 durch Anakinra, Canakinumab und Rilonacept, Interleukin 6 durch Tocilizumab oder der Inhibition der T-Zellaktivierung durch Abatacept. In dieser Übersichtsarbeit werden die pharmakologischen Therapieoptionen orientierend an der Existenz von kontrollierten randomisierten Studien dargestellt.

Summary

Treatment of juvenile idiopathic arthritis consists of a combination therapy including non-steroidal antirheumatics, glucocorticoids either systemic or intraarticular, classical disease modifying drugs like sulfasalazine and methotrexate as well as leflunomide and biologicals. These new therapeutic strategies have effected dramatic improvements also in patients with severe, so far intractable disease. Three TNF inhibitors etanercept, adalimumab and infliximab have already been studied. Further treatment options include inhibitors of interleukin 1 (anakinra, canakinumab and rilonacept), interleukin 6 (tocilizumab) and inhibitors of T-cell activation (abatacept). This review will summarize the pharmacotherapeutic options based on studies published in the literature.

Schlüsselwörter

Juvenile idiopathische Arthritis - Etanercept - Adalimumab - Infliximab - Anakinra - Tocilizumab - Abatacept

Keywords

Juvenile idiopathic arthritis - Etanercept - Adalimumab - Infliximab - Anakinra - Tocilizumab - Abatacept
 

  • Literatur

  • 1 Ansell BM, Hall MA, Loftus JK. et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 201-203.
    PubMedGoogle Scholar
  • 2 Armbrust W, Kamphuis SS, Wolfs TW. et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004; 43: 527-529.
    CrossrefPubMedGoogle Scholar
  • 3 Balis FM, Mirro Jr J, Reaman GH. et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-1886.
    CrossrefPubMedGoogle Scholar
  • 4 Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269-1276.
    CrossrefPubMedGoogle Scholar
  • 5 Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C. et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 2002; 61: 941-942.
    CrossrefPubMedGoogle Scholar
  • 6 Giannini EH, Brewer EJ, Kuzmina N. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med 1992; 326: 1043-1049.
    CrossrefPubMedGoogle Scholar
  • 7 Giannini EH, Ruperto N, Prieur AM. et al. Efficacy and Safety of Abatacept in Children and Adolescents with Active Juvenile Idiopathic Arthritis (JIA): Results of Double-Blind Withdrawal Phase. 2006 Annual Scientific meeting of the American College of Rheumatology, October 16-21., Washington, USA. Arthritis Rheum 2006; 54: S482
    CrossrefPubMedGoogle Scholar
  • 8 Giannini EH, Ruperto N, Ravelli A. et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-1209.
    CrossrefPubMedGoogle Scholar
  • 9 Goldbach-Mansky R, Dailey NJ, Canna SW. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-589.
    CrossrefPubMedGoogle Scholar
  • 10 Lovell DJ, Gianinni EH, Kimura Y. et al. Prelimonary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2006; 54: S325
    CrossrefPubMedGoogle Scholar
  • 11 Heiligenhaus A, Mingels A, Neudorf U, Ganser G. Juvenile idiopathic arthritis and uveitis: screening and anti-inflammatory therapy. Klin Monatsbl Augenheilkd 2003; 220: 738-753.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Horneff G, De Bock F, Foeldvari I. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2008. Apr 15 [Epub ahead of print]
    Google Scholar
  • 13 Horneff G, Minden K, Foeldvari I. et al. Safety and efficacy of once weekly Etanercept 0.8 mg/kg: Interim analysis of an multicentra 12 weeks open trial in active juvenile idiopathic arthritis. Ann Rheum Dis 2008; 64 (Suppl)
    PubMedGoogle Scholar
  • 14 Horneff G, Schmeling H, Biedermann T. et al. The German Etanercept Registry for Treatment of Juvenile Idiopathic Arthritis (JIA). Ann Rheum Dis 2004; 63: 1638-1644.
    CrossrefPubMedGoogle Scholar
  • 15 Horneff G. Einsatz von Biologika bei der juvenilen idiopathischen Arthritis. Konsensusstatement des 7. Wörlitzer Expertengespräches 2004 für die Arbeitsgemeinschaft Kinder- und Jugendrheumatologie. Monatsschr Kinderheilkd 2005; 153: 473-479.
    CrossrefGoogle Scholar
  • 16 Horneff G. Wirksamkeit und Verträglichkeit der Therapie mit Methotrexat bei Patienten mit juveniler idiopathischer Arthritis – Analyse aus dem Deutschen Methotrexatregister. Tagung der Gesellschaft Kinder- und Jugendrheumatologie, Meerbusch 2007
    Google Scholar
  • 17 Jundt JW, Browne BA, Fiocco GP. et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-1849.
    Google Scholar
  • 18 Kay J, Matteson EL, Dasgupta B. et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis & Rheumatism 2008; 58 (04) 964-975.
    CrossrefPubMedGoogle Scholar
  • 19 Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007; 28: 153-156.
    CrossrefPubMedGoogle Scholar
  • 20 Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol 1986; 13: 118-123.
    Google Scholar
  • 21 Lovell DJ, Giannini EH, Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763-769.
    CrossrefPubMedGoogle Scholar
  • 22 Lovell DJ, Reiff A, Jones OY. et al. Long-term safety and efficacy of etanercept in children with poly-articular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006; 54: 1987-1994.
    CrossrefPubMedGoogle Scholar
  • 23 Lovell DJ, Ruperto N, Goodman S. et al Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-820.
    CrossrefPubMedGoogle Scholar
  • 24 Lovell DJ, Ruperto N, Prieur AM. et al. Assessment of open label co-stimulation blockade with Abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis Rheum 2006; 54: S326
    Google Scholar
  • 25 Manger B. Kommission Pharmkotherapie, Deutsche Gesellschaft fur Rheumatologie. Revised recommendations of the Deutsche Gesellschaft fur Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases. Z Rheumatol 2002; 61: 694-697.
    CrossrefPubMedGoogle Scholar
  • 26 Niehues T, Horneff G, Michels H. et al. Evidenzbasierter Einsatz von Methotrexat bei Kindern mit rheumatischen Erkrankungen. Konsensusstatement der Arbeitsgemeinschaft Kinder- und Jugendrheumatologie Deutschland (AGKJR) und Arbeitsgemeinschaft Pädiatrische Rheumatologie Österreich. Monatsschr Kinderheilkd 2003; 151: 881-890.
    CrossrefGoogle Scholar
  • 27 Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007; 66 (05) 704-705.
    CrossrefPubMedGoogle Scholar
  • 28 Quartier P, Allantaz F, Cimaz R. et al. Anakinra in systremic onset juvenile idiopathic arthritis: result of a multienter doubleblind trial (ANAJIS). Ann Rheum Dis 2008; 68 (Suppl)
    Google Scholar
  • 29 Quartier P, Taupin P, Bourdeaut F. et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-1101.
    CrossrefPubMedGoogle Scholar
  • 30 Ruperto N, Lovell DJ, Quartier P. et al Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-391.
    CrossrefPubMedGoogle Scholar
  • 31 Ruperto N, Murray KJ, Gerloni V. et al Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-2201.
    CrossrefPubMedGoogle Scholar
  • 32 Ruperto N, Ravelli A, Castell E. et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol 2006; 5: 599-605.
    Google Scholar
  • 33 Silverman E, Mouy R, Spiegel L. et al. Leflunomide in Juvenile Rheumatoid Arthritis (JRA) Investigator Group. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655-1666.
    CrossrefPubMedGoogle Scholar
  • 34 van der Meer A, Wulffraat NM, Prakken BJ. et al. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. Clin Exp Rheumatol 2007; 25: 480-485.
    PubMedGoogle Scholar
  • 35 Van Rossum MA, Fiselier TJ, Franssen MJ. et al. Sulfasalzin in the treatment of juvenile chronic arthritis. A randomized double-blind placebo-controlled multicenter study. Arthritis Rheum 1998; 41: 808-816.
    CrossrefPubMedGoogle Scholar
  • 36 Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-2294.
    Google Scholar
  • 37 Woo P, Southwood TR, Prieur AM. et al. Random-ized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2005; 43: 1849-1857.
    Google Scholar
  • 38 Yokota S, Imagawa T, Mori M. et al. Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results of a Tocilizumab sJIA phase III clinical trial. Arthritis Rheum 2006; 54: S327
    Google Scholar